341 related articles for article (PubMed ID: 32015035)
1. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
2. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection.
Viasus D; Puerta-Alcalde P; Cardozo C; Suárez-Lledó M; Rodríguez-Núñez O; Morata L; Fehér C; Marco F; Chumbita M; Moreno-García E; Fernández-Avilés F; Gutiérrez-Garcia G; Martínez JA; Mensa J; Rovira M; Esteve J; Soriano A; Garcia-Vidal C
Clin Microbiol Infect; 2020 Mar; 26(3):345-350. PubMed ID: 31295551
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
[TBL] [Abstract][Full Text] [Related]
6. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
7. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Chumbita M; Puerta-Alcalde P; Yáñez L; Angeles Cuesta M; Chinea A; Español-Morales I; Fernandez-Abellán P; Gudiol C; González-Sierra P; Rojas R; Sánchez-Pina JM; Vadillo IS; Sánchez M; Varela R; Vázquez L; Guerreiro M; Monzo P; Lopera C; Aiello TF; Peyrony O; Soriano A; Garcia-Vidal C
Microbiol Spectr; 2023 Aug; 11(4):e0067423. PubMed ID: 37367629
[TBL] [Abstract][Full Text] [Related]
8. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
[TBL] [Abstract][Full Text] [Related]
10. Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa.
Appaneal HJ; Caffrey AR; Lopes V; Piehl EC; Puzniak LA; LaPlante KL
Microbiol Spectr; 2022 Oct; 10(5):e0233622. PubMed ID: 36005836
[TBL] [Abstract][Full Text] [Related]
11. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
[TBL] [Abstract][Full Text] [Related]
12. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
13. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
14. Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Kleinhendler E; Cohen MJ; Moses AE; Paltiel O; Strahilevitz J; Cahan A
Int J Antimicrob Agents; 2018 Jan; 51(1):71-76. PubMed ID: 28705670
[TBL] [Abstract][Full Text] [Related]
15. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
[TBL] [Abstract][Full Text] [Related]
18. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.
Peña C; Gómez-Zorrilla S; Suarez C; Dominguez MA; Tubau F; Arch O; Oliver A; Pujol M; Ariza J
Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2791-7. PubMed ID: 22552893
[TBL] [Abstract][Full Text] [Related]
19. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center.
Marín M; Gudiol C; Garcia-Vidal C; Ardanuy C; Carratalà J
Medicine (Baltimore); 2014 May; 93(3):143-149. PubMed ID: 24797169
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
Yan LZ; Herrington JD
J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
